Pharvaris Reports Third Quarter 2026 Financial Results
Pharvaris announced its financial results for the third quarter ended September 30, 2026, reporting a cash and cash equivalents position of €283 million.
Stocks · News reference
Pharvaris presented new clinical and real-world data for its lead candidate, deucrictibant, at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pharvaris announced its financial results for the third quarter ended September 30, 2026, reporting a cash and cash equivalents position of €283 million.
Analysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
Pharvaris announced that it will present one oral presentation and five poster presentations featuring clinical and real-world data at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting.
Analysts upgraded SAFE, CNOB, LMT and more.
BofA Securities has upgraded its rating for Pharvaris N.V. from Neutral to Buy, according to a report published on October 23, 2026.
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR showed a